FDA warns Forest Labs about Bystolic ads

Forest Laboratories Inc. received a warning letter from the FDA near the end of August for failure to show the risks of its high blood pressure medication, Bystolic, when promoting the drug to physicians.

The company ran an eight-page ad in a variety of medical journals favorably comparing the medication to other medications, but without enough research to support their claims. The advertisements omitted and minimized some of the risks associated with the drug--including cardiac failure and chest pain, as well as claimed the drug was superior for use in patients with obesity, diabetes and poor metabolism--without sufficient evidence to do so, according to the FDA. 

Share prices also dropped following legal claims on the Bystolic patent.

- catch the Forbes.com story
- read the Pharmalot blog post

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.